<http://schema.org/description>
"In patients with non-ST-elevation acute coronary syndrome (NSTE- ACS), pre-treatment with the P2Y12 antagonist prasugrel prior to catheterization, significantly increases the risk of life-threatening bleeding without reducing the risk of major ischemic events, according to the results of the ACCOAST (A Comparison of Prasugrel at PCI or Time of Diagnosis of Non-ST Elevation Myocardial Infarction) trial."^^<http://www.w3.org/2001/XMLSchema#string>
<http://medicalxpress.com/news/2013-09-pre-treatment-prasugrelmore-benefit-accoast.html>